Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07719907

Clinical Pharmacist-Led Bundled Care Model on Preventable Polypharmacy and Cost Avoidance

This study aims to evaluate whether a clinical pharmacist-led bundled care model can improve medication use and health outcomes in hospitalized adult patients with preventable polypharmacy. Preventable polypharmacy refers to the use of multiple medications when some may no longer be necessary, may be inappropriate, or may increase the risk of medication-related harm.

Participants will be randomly assigned to receive either the pharmacist-led bundled care intervention in addition to usual hospital care or usual hospital care alone. The intervention includes comprehensive medication reconciliation, assessment of medication appropriateness, identification of potentially inappropriate medications, individualized deprescribing recommendations when appropriate, patient and caregiver education, discharge medication reconciliation, and follow-up after hospital discharge.

The study will compare important clinical outcomes between the two groups, including hospital readmissions, emergency department visits, adverse drug events, medication appropriateness, quality of prescribing, and healthcare costs. The findings will help determine whether integrating a clinical pharmacist-led bundled care model into routine hospital practice can improve patient safety, optimize medication use, and reduce unnecessary healthcare utilization.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Medication-related Problems

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 years or older.
  • Admitted under an adult medical specialty at one of the participating hospitals.
  • Receiving five or more regular medications at the time of hospital admission.
  • Expected hospital stay of at least 48 hours.
  • Able and willing to provide written informed consent.

Exclusion criteria

  • Admission under obstetric, pediatric, or psychiatric services.
  • Admission to an intensive care unit.
  • Terminal illness with an expected survival of less than three months.
  • Unable to provide informed consent and without an available legal representative.
  • Declines participation in the study.

Treatment and study plan

Clinical Pharmacist-Led Bundled Care

Other

Participants randomized to the intervention arm will receive a structured clinical pharmacist-led bundled care model in addition to usual hospital care. The intervention includes medication reconciliation at admission, comprehensive medication review, identification and resolution of medication-related problems, assessment of medication appropriateness using validated tools, deprescribing of potentially inappropriate medications when clinically indicated, dose optimization, evaluation of drug-drug interactions and medication safety, individualized pharmaceutical care planning, participation in multidisciplinary care with recommendations to the treating team, patient and caregiver medication counseling, discharge medication reconciliation, provision of an updated medication list, and post-discharge follow-up to reinforce medication adherence, identify medication-related problems, and optimize ongoing therapy. All interventions will be delivered according to a standardized study protocol

Control arm (Usual care)

Other

Participants randomized to the control arm will receive usual hospital care provided according to the standard practices of the participating institutions. This includes routine medical and nursing care, medication prescribing and review by the treating healthcare team, and standard discharge processes. No structured clinical pharmacist-led bundled care intervention, standardized comprehensive medication review, protocol-driven deprescribing, or post-discharge pharmacist follow-up will be provided as part of the study. Clinical pharmacy services that are routinely available at the participating hospitals may be provided as part of usual care but will not follow the standardized intervention protocol.

Primary outcomes

  1. Total Healthcare Cost Avoidance per Participant

    Time frame: 90 days after hospital discharge

    The difference between the intervention and control groups in total healthcare cost avoidance per participant associated with the clinical pharmacist-led bundled care model. Total cost avoidance will include direct medication and investigation cost reductions and indirect costs avoided through prevention of adverse drug events, reduced hospital length of stay, and reductions in unplanned hospital readmissions and emergency department visits.

    Cost avoidance will be calculated using institutional healthcare utilization and costing data and standardized cost-avoidance values for accepted pharmacist interventions.

  2. Prevalence of Preventable Polypharmacy at Hospital Discharge

    Time frame: through study completion, an average of 1 week during admission

    The proportion of participants with one or more unnecessary, inappropriate, duplicative, or potentially harmful medications at hospital discharge, compared between the pharmacist-led bundled care group and the usual-care group. Preventable polypharmacy will be assessed using predefined clinical criteria, comprehensive medication review, and validated medication-appropriateness tools.

Secondary outcomes

  1. Number of Medications Deprescribed per Participant

    Time frame: through study completion, an average of 1 week during admission

    The number of unnecessary, inappropriate, duplicative, or potentially harmful medications discontinued following medication review. Only deprescribing recommendations accepted and implemented by the treating medical team will be counted.

  2. Incidence of Adverse Drug Events

    Time frame: From hospital admission through 90 days after discharge

    During the index hospitalization and at 90 days after hospital discharge

  3. All-Cause Hospital Readmission

    Time frame: 30 days and 90 days after hospital discharge

    The proportion of participants with at least one unplanned all-cause hospital readmission following discharge, compared between the intervention and control groups.

Other outcomes

  1. Number of Medication-Related Problems Identified and Resolved

    Time frame: through study completion, an average of 1 week during admission

    The number and type of medication-related problems identified by clinical pharmacists and the proportion resolved following acceptance and implementation of pharmacist recommendations.

Sponsors and collaborators

Lead sponsor

Sultan Qaboos University

Other

Registry information

Official study title

Impact of a Clinical Pharmacist-Led Bundled Care Model on Preventable Polypharmacy and Cost Avoidance Among Hospitalized Adults in Oman: A Prospective Randomized Controlled Study

Important dates

Study start
2027
Primary completion
2027
Study completion
2028
First posted
Jul 22, 2026
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.